The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...

Shares of Biocon experienced a decline of 2.01% to Rs 386.70 in Tuesday's session, with the stock figuring among the top ...

RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

With the stock currently trading at Rs 405.05, Biocon has demonstrated strong financial performance and positive investor sentiment, as reflected by its 52-week high and bullish market outlook.

The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

The global Biosimilars Market , valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Fundraising through qualified institutional placements (QIPs) saw a revival in June after a tepid first five months of 2025, ...

Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration has approved Kirsty™ (Insulin Aspart-xjhz), ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...